View Future GrowthAton 과거 순이익 실적과거 기준 점검 0/6Aton 의 수입은 연평균 -20.1%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 13.3%의 비율로 증가했습니다. 매출은 연평균 102%의 비율로 증가해 왔습니다.핵심 정보-20.06%순이익 성장률-4.07%주당순이익(EPS) 성장률Biotechs 산업 성장률-14.59%매출 성장률102.01%자기자본이익률-15.27%순이익률-17.61%최근 순이익 업데이트30 Jun 2025최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updatesNew Risk • May 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (162% average daily change). Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m (€657k revenue, or US$763k). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (€12.4m market cap, or US$14.4m).New Risk • Nov 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 38% per year over the past 5 years. Revenue is less than US$1m (€614k revenue, or US$714k). Market cap is less than US$10m (€6.04m market cap, or US$7.01m). Minor Risk Latest financial reports are more than 6 months old (reported December 2024 fiscal period end).공시 • May 21Aton, Annual General Meeting, Jun 30, 2025Aton, Annual General Meeting, Jun 30, 2025. Location: 850 boulevard sebastien brant, illkirch graffenstaden FranceNew Risk • Nov 14New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.42m (US$9.91m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (162% increase in shares outstanding). Market cap is less than US$10m (€9.42m market cap, or US$9.91m).New Risk • Jul 24New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 163% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (61% average daily change). Shareholders have been substantially diluted in the past year (163% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€9.49m market cap, or US$10.3m).New Risk • May 19New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (47% average weekly change). Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Market cap is less than US$10m (€4.00m market cap, or US$4.35m).New Risk • Nov 07New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.44m (US$9.02m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (€8.44m market cap, or US$9.02m). Minor Risk Shareholders have been diluted in the past year (13% increase in shares outstanding).New Risk • Oct 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (9.1% average weekly change). Minor Risks Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (€13.3m market cap, or US$14.0m).New Risk • Jul 23New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 11% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (€15.9m market cap, or US$17.7m).공시 • May 07Hybrigenics Société Anonyme announced that it has received fundingHybrigenics Société Anonyme (ENXTPA:ALHYG) announced that it has received a round of funding on May 6, 2021. The company has issued common stock in the transaction.Is New 90 Day High Low • Feb 25New 90-day high: €0.30The company is up 47% from its price of €0.20 on 27 November 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 7.0% over the same period.Is New 90 Day High Low • Feb 10New 90-day high: €0.23The company is up 31% from its price of €0.18 on 11 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period.Is New 90 Day High Low • Jan 20New 90-day high: €0.22The company is up 19% from its price of €0.19 on 22 October 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period.Is New 90 Day High Low • Nov 25New 90-day high: €0.21The company is up 18% from its price of €0.18 on 26 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 8.0% over the same period.매출 및 비용 세부 내역Aton가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이BST:3HB 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비30 Jun 25101031 Mar 251-11031 Dec 241-11030 Sep 241-31030 Jun 240-160031 Mar 240-170031 Dec 231-82031 Dec 220-10031 Dec 21000031 Dec 20000031 Dec 190-11031 Dec 180-830양질의 수익: 3HB 은(는) 현재 수익성이 없습니다.이익 마진 증가: 3HB는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 3HB은 수익성이 없으며 지난 5년 동안 손실이 연평균 20.1% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 3HB의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 3HB은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(39.9%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 3HB는 현재 수익성이 없으므로 자본 수익률이 음수(-15.27%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/24 11:45종가2026/05/22 00:00수익2025/06/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Aton는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
New Risk • May 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (162% average daily change). Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m (€657k revenue, or US$763k). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (€12.4m market cap, or US$14.4m).
New Risk • Nov 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 38% per year over the past 5 years. Revenue is less than US$1m (€614k revenue, or US$714k). Market cap is less than US$10m (€6.04m market cap, or US$7.01m). Minor Risk Latest financial reports are more than 6 months old (reported December 2024 fiscal period end).
공시 • May 21Aton, Annual General Meeting, Jun 30, 2025Aton, Annual General Meeting, Jun 30, 2025. Location: 850 boulevard sebastien brant, illkirch graffenstaden France
New Risk • Nov 14New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.42m (US$9.91m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (162% increase in shares outstanding). Market cap is less than US$10m (€9.42m market cap, or US$9.91m).
New Risk • Jul 24New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 163% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (61% average daily change). Shareholders have been substantially diluted in the past year (163% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€9.49m market cap, or US$10.3m).
New Risk • May 19New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (47% average weekly change). Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Market cap is less than US$10m (€4.00m market cap, or US$4.35m).
New Risk • Nov 07New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.44m (US$9.02m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (€8.44m market cap, or US$9.02m). Minor Risk Shareholders have been diluted in the past year (13% increase in shares outstanding).
New Risk • Oct 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (9.1% average weekly change). Minor Risks Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (€13.3m market cap, or US$14.0m).
New Risk • Jul 23New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 11% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (€15.9m market cap, or US$17.7m).
공시 • May 07Hybrigenics Société Anonyme announced that it has received fundingHybrigenics Société Anonyme (ENXTPA:ALHYG) announced that it has received a round of funding on May 6, 2021. The company has issued common stock in the transaction.
Is New 90 Day High Low • Feb 25New 90-day high: €0.30The company is up 47% from its price of €0.20 on 27 November 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 7.0% over the same period.
Is New 90 Day High Low • Feb 10New 90-day high: €0.23The company is up 31% from its price of €0.18 on 11 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period.
Is New 90 Day High Low • Jan 20New 90-day high: €0.22The company is up 19% from its price of €0.19 on 22 October 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period.
Is New 90 Day High Low • Nov 25New 90-day high: €0.21The company is up 18% from its price of €0.18 on 26 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 8.0% over the same period.